Enterprise Value
-56.87M
Cash
246.7M
Avg Qtr Burn
-19.84M
Short % of Float
6.60%
Insider Ownership
9.20%
Institutional Own.
80.18%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Nulabeglogene autogedtemcel (nula-cel) (GPH101) Details Sickle cell disease | Failed Discontinued |